Cargando…
奥希替尼联合贝伐珠单抗在获得性EGFR T790M突变晚期非小细胞肺癌的疗效分析
BACKGROUND AND OBJECTIVE: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) capable of overcoming non-small cell lung cancer (NSCLC) with EGFR T790M mutation. Although the addition of bevacizumab to 1(st) generation EGFR-TKIs confers a signific...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845088/ https://www.ncbi.nlm.nih.gov/pubmed/36617470 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.56 |